

EXPRESS MAIL LABEL NO. EV 765 976 315 US DATE MAILED: November 28, 2006

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97**

## MAIL STOP RCE

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

12/01/2006 MBELETE1 00000019 081641 10006116

01 FC:1806

180.00 DA

	This st	atement o	qualifies	under 37 C.F.R	R. §1.97	, subs	ection (	b) becau	se (che	ck all t	hat apply	);
			(1) than a c	It is being filed continued prosection OR						filing d	ate and is	other
			(2)	It is being filed	withir	ı 3 mo	nths of	entry of	a nation	nal stag	ge .	
			(3) merits	OR It is being filed	l before	the n	nail date	of the f	irst Off	ice Act	ion on the	e
			(4) of a req	OR It is being filed uest for continu			-			Action	after the	filing
⊠	37 C.F.R. $\S1.97(c)$ . If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$ , then:											
		a certifi	cation a	s specified in §1	l.97(e)	is pro	vided be	elow; or		•		
٠				as set forth in so						ed, or i	ncluded v	with
		action und		his statement is 13 or a notice of								
	A.	a certifi	cation a	s specified in §1	l.97(e)	is con	npleted	below; a	nd			
	B.			37 C.F.R. §1.9° vith; <b>and</b>	7(d) red	questii	ng consi	deration	of this	statem	ent is	
	C.			as set forth in so						osed, o	r include	d with
	of <b>\$18</b> 0	0.00 and o	charge a	Commissioner ny additional fesit Account No.	es or c	redit a	ny over	paymen	t associ	ated wi	th this	
					]	Respe	ctfully s	ubmitte	d,			
Dated:	Novem	nber 28, 2	006	·	By:	及' Barrie	D. Gree	ene (Reg	g. No. 4	6,740)	·	
275 Mi	ddlefiel	RMAN L d Road alifornia		3506								

-2-

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

					XI					201 1 01 0	
		Form PTO-14	449 \ NOF	d	Attorney's Docket No.			lication Seria	il No.		
			St.	- CARD	39780-2830 P1C15		10/0	006,116			
INFO	RMATIC	ON DISCLOSU	IRE STATEMENT		Applicant(s)						
						Kevin P. BAK	r		<del></del>		
					Filing Date:			up Art Unit:			
	(use sei	veral sheets if	f necessary)		December 6, 2001		163	<u> 6                                    </u>			
· ·				<u> </u>	S. PATENT DOCUMENTS						
Examiner	Ref.	Date	Document No.	1	Name	C	ass	Subclass	Filing Date		
Initials	No.								(if appropr	riate)	
	<u> </u>										
					IGN PATENT DOCUMENTS						
Examiner	Ref.	Date	Document No.		Name	C	ass	Subclass	Translation		
Initials	No.				•				YES	NO	
									<u> </u>		
	<u> </u>										
					OTHER DOCUMENTS						
			(includ	ling au	thor, title, date, pertinent page	es, etc.)					
Examiner	Ref.	Title							•		
Initials	No.										
	1.				obility Group A2 Expression L		ted w	ith malignan	t Phenotype	in	
	ļ				ncer - 89(11):2104-9 (2003) Ab			:			
*	2.			ptosis	of Natural Killer-Cell Tumours	s by I-Asparagi	nase,	" Br J Haema	itol., - <u>130(6)</u>	:860-8	
		(2005) Abstr				·			1.41		
	3.	Aust, G., et a	Aust, G., et al., "Human Thyroid Carcinoma Cell Lines and Normal Thyrocytes: Expression and Regulation of Matrix Metalloproteinase Inhibitor-1 Messenger-RNA and Protein," <i>Thyroid</i> - 7(5):713-24 (1997) Abstract.								
	-	Rarnos VI	et al "Expression	nesser	mbryonic Fibronectin Isoform	EIIIA Parallele	Alpha	Abstract.	aala Aatin in		
	4.				stochem Cytochem <u>47(6</u> ):78				Scie Acum in	l	
	<u> </u>				tion and Overexpression in He				Mainly in Ma	antle	
	5.				):2409-12 (2001) Abstract.	a.o.og.ou	ugc		manny m m	411110	
		Blaschke, V., et al., "Rapid Quantitation of Proinflammatory and Chemoattractant Cytokine Expression in Small Tissue									
	6.	Samples and Monocyte-Derived Dendritic Cells: Validation of a New Real-Time RT-PCR Technology," <i>J Immunol</i>									
	1	Methods 246(1-2):79-90 (2000) Abstract.									
	7.	Buckley, A.R	R., et al., "Butyrate	-Induc	ed Reversal of Dexamethason	e Resistance in	Auto	nomouse Ra	t Nb2 Lymph	noma	
	<b>'</b> '-	Cells," Apop	otosis <u>2(6)</u> :518-28	3 (1997	) Abstract.						
	8.	Caberlotto, L	L. <i>et al.,</i> "Alteration	s in Ne	europeptide Y Levels and Y1 B	inding Sites in	the F	linders Sensi	tive Line Ra	ts, A	
	ļ				," Neurosci Lett <u>265(3)</u> :191-4						
	9.				eceptor and Relative Abundan	ce of the Short	and I	ong Isoform	s in the Hun	nan	
	-		J Neurosci <u>17(9)</u> :								
	10.			on of (	Cyclin D2 Expression in Humar	n Endometrium	," <i>J</i> S	oc Gynecol l	nvestig <u>9(</u>	<u>1)</u> :41-6	
· ·	<del> </del>	(2002) Abstr		\h a vi a v	is Considerantia Deta Francia						
	11.		3):279-84 (2004) Al		nic Gonadotrophin Beta Expre	ssion in Mailgr	iant B	arreπ's Oeso	pnagus," Vi	rcnows	
*****	<del> </del>				of EnaC Activity and Expressi	on by TNE-Ala	ha in	Alvoolar Enit	holial Calle	' Am 1	
	12.				2):L301-11 (2004) Abstract.	ion by TNE-AIP	iia III	Aiveolal Epit	nenai Cens,	AIII J.	
	13.				he CCNDI Gene in Hairy Cell L	eukemia " Ann	Once	1 7/3)-251.	6 (1996) Ahe	tract	
	13.								:		
	14.				n Production and Subunit Exp	ression in Hun	nan Pl	acental Cells	Cultured in	Vitro,"	
	<del>                                     </del>		<i>prod.</i> - <u>6(8)</u> :743-9 (		Abstract. Frane-Type Matrix Metalloprote	inacoc A E	4 6 i~	Mouse Corr	one Infected	with D	
	15.				rane-Type matrix metalloprote ci - 42(13):3223- (2001) Abstrac		u o in	wouse Corn	eas intected	WITH P.	

EXAMINER:	DATE CONSIDERED:
•	
EXAMINER: Initial if citation considered, whether or not the citation conf	forms with MPEP 609. Draw a line through the citation if not in

conformance and not considered, whether of not the challon conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered, whether of the challon conformance and not considered.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2244524 v1

Form PTO-1449		Attorney's Docket No.	Application Serial No.	
		39780-2830 P1C15	10/006,116	
INFORMATIO	N DISCLOSURE STATEMENT	Applicant(s)		
		Kevin P. BAK	ER, et al.	
		Filing Date:	Group Art Unit:	
(use sev	eral sheets if necessary)	December 6, 2001	1636	
		OTHER DOCUMENTS		
		hor, title, date, pertinent pages, etc.)		
16.		roliferative Activity in Colorectal Carcinoma		
10.		ction (RT-PCR)," Cancer Invest 19(6):588-9		
17.		ation of Carbohydrate Digestion and Absorp	tion in Equine Small Intestine,"	
	Equine Vet J 34(4):349-58 (2002) Abs		U. 5	
18.		f Cytokine Signaling Proteins are Differentia		
		nitment and Maintenance," <i>J Immunol.</i> - <u>168</u> ading Cells Contribute to Vitreal Cytokine M		
19.	Vitreoretinopathy," Br J Opthalmol		med in Fromerative	
		lutamatergic Receptors (AMPA and NMDA) a	and of Glutamate Vesicular	
20.	1	is after Axotomy," Neuroscience - 136(1):14		
		Scavenging Enzymes in Embryos Subjected		
21.	Radic Res 24(6):451-9 (1996) Abstra		",	
22		e Estrogen Receptor by Growth Hormone ar	nd Glucocorticoid Substitution in	
22.	Priminary Cultures of Rat Hepatocytes	s," <i>Endocrinology</i> - <u>133(4)</u> :1548-54 (1993) Al	ostract.	
23.		tle Cell Lymphoma: A Clinocopathologic St	udy Based on Gene Expression	
20.	Profiling," Blood - 106(13):4315-21 (20			
24.		rs in Bovine Cervix: Distrubution and Gene	Expression During the Estrous	
	Cycle," Biol Reprod 54(3):700-8 (199		H 46 4 5 6 45 40 45 60	
25.		ombomodulin Gene in Human Malignant Mel	anoma," <i>Welanoma Res.</i> - <u>15(1)</u> :15-20	
00	(2005) Abstract.	Yeast Proteome," Mol Cell Biol., - 19(11):735	7-68 (1999) Abstract	
26.			· · · · · · · · · · · · · · · · · · ·	
27		egulation of Cytochrome P450 Genes is Res		
27.	Abstract.	Among Patients with Cirrhosis," Biochem Pa	narmacol <u>49(7)</u> :873-81 (1995)	
	<u> </u>	Expression in Macrophages: Modulation by	Protein Kinggo C alpha " Limmuno!	
28.	165(7):3985-91 (2000) Abstract.	Expression in Macrophages. Modulation by	Protein Killase C-alpha, Jillillanoi	
		filing of Human Platelets Using Microarray a	nd Serial Analysis of Gene	
29.	Expression," <i>Blood</i> - 101(6):2285-93 (2		na conai ranaiyoto or cono	
20		of DEAD Box Protein (DDX1) in Neuroblaston	na and Retinoblastoma Cell Lines," J	
30.	Biol Chem, - 273(33):21161-8 (1998) A			
31.	Goldenberg, R.C., et al., "Modulation	of Gap Junction Mediated Intercellular Com	munication in TM3 Leydig Cells," J	
31.	Endocrinol 177(2):327-35 (2003) Abs			
32.		evel of Ubc9 Protein in Rat Tissues," Acta Bi	ochim Pol <u>50(4)</u> :1065-73 (2003)	
	Abstract.			
33.		Thymidylate Synthase, and Dihydropyrimidi		
		s Anticancer Drug Screen," Clin Cancer Res		
34.	•	Adenomas," Regul Pept, - 117(2):127-39 (20	<b>'</b>	
35.		e and mRNA Levels of the Adipocyte-Type F		
		ansitional Cell Carcinomas," Int J. Oncol 1		
36.		of Macrophage Migration Inhibitory Factor in	Acute Respiratory Distress	
	Syndrome," Zhinghua Jie He He Hu X	Za Zni - <u>Z5(b)</u> :33/-40 (2002) Abstract.		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation cor	forms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2244524 v1

	Form PTO-1449	Attorney's Docket No.	Application Serial No.	
		39780-2830 P1C15	10/006,116	
INFORMATIO	N DISCLOSURE STATEMENT	Applicant(s)		
•		Kevin P. BAK	ER, et al.	
		Filing Date:	Group Art Unit:	
(use sev	reral sheets if necessary)	December 6, 2001	1636	
		THER DOCUMENTS		
		hor, title, date, pertinent pages, etc.)		
		and Activity of Organic Ion Transporters rO	AT1. rOAT3 and rOCT2 after	
37.		chem Pharmacol - 69(6):993-9 (2005) Abstra		
		chrome P4501A1 in Teleosts: Sustained Indu		
38.	Catalytic Activity by 2,3,7,8-Tetrachlor	odibenzofuran in the Marine Fish Stenotomu	us Chrysops," <i>Toxicol Appl</i>	
	Pharmacol 127(2):187-98 (1994) Abs			
39.	Hahnel, R., et al., "Expression of the p	S2 Gene in Breast Tissues Assessed by pS2	-mRNA Analysis and pS2-Protein	
39.	Radioimmunoassay," Breast Cancer R			
40.		Epidermal Growth Factor Receptor in Sustai	ning Neutrophil Inflammation in	
40.	Severe Asthma," Clin Exp Allergy 33			
41.		crosomal Epoxide Hydrolase: Comparative A	nalysis of Polymorphic Expression,"	
7"	Arch Biochem Biophys 337(2):275-8			
42.		ation of Tissue Inhibitor of Metalloproteinas	es 1 (TIMP-1) in Human Colorectal	
72.		Cance, - 113(2):198-206 (2005) Abstract.		
43.		en Activator Induced by Dengue Virus Infect	ion of Human Endothelial Cells," J	
	Med Virol 70(4):610-6 (2003) Abstrac			
44.		Expression in Ovarian Tumors: A Quantitativ	ve Study," <i>Mod Pathol.</i> - <u>5(3)</u> :250-6	
	(1992) Abstract.	<u> </u>		
45.	Hui, P., et al., "Real-time Quantitative I	RT-PCR of Cyclin D1 mRNA in Mantle Cell Ly	mphoma: Comparison with FISH and	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Immunohistochemistry," Leuk Lymph			
40		merase I Messenger RNA, Protein, and Cata		
46.		city and Implications for Cancer Chemothera	py," <i>Cancer Res.</i> - <u>54(2)</u> :539-46	
	(1994) Abstract.	uantification of Proliferation Marker pKi-67 is	Correlated with Favorable	
47.		l Cancer Res Clin Oncol <u>130(12)</u> :749-56 (20		
		agon Receptor Expression and Response in		
48.		iol <u>281(4)</u> :C1396-402 (2001) Abstract.	Transfected Human Embryonic	
		Regulation of Acidic Fibroblast Growth Fact	or (aEGE) Expression in Boying	
49.	Retina," Int J Biol 37(3):417-23 (1993		or (at or / Expression in Bovine	
· · · · · · · · · · · · · · · · · · ·		in, A Cyclin Inhibitor, Regulates the Levels a	and the Intracellular Localization of	
50.	CDC25A in Mice Regenerating Livers.	' <i>Hepatology</i> - <u>35(5)</u> :1063-71 (2002) Abstract.	and the intracential Localization of	
		zled Expression in renal Cell Carcinoma," Tu		
51.	Abstract.	Elou Expression in relia. Cen Guienionia,	our Biol <u>25(4)</u> . 101-11 (2004)	
		hemical Analysis of NY-ESO-1 Antigen Expr	ession in Normal and Malignant	
52.	Human Tissues," Int J. Cancer - 92(6):	856-60 (2001) Abstract.	ooololi iii itoililai aha manghant	
		ance Phosphoglycoprotein (ABCB1) in the M	Jouse Placenta: Fetal Protection "	
53.	Biol Reprod 73(4):591-7 (2005) Abstr			
	Kammaori, M., et al., "Expression of H	uman Telomerase Reverse Transcriptase Ge	ene and Protein, and of Estrogen amd	
54.	Progesterone Receptors, in Breast Tu	mors: Preliminary Data from Neo-Adjuvant C	Chemotherapy," Int J Oncol	
	27(5):1257-63 (2005) Abstract.			
55.	Khal, J., et al., "Expression of the Ubic	uitin-Proteasome Pathway and Muscle Loss	in Experimental Cancer Cachexi." Br	
JJ.	J Cancer - 93(7):774-80 (2005), Abstra			
56.		of Proteasome Subunits in Skeletal Muscle o	of Cancer Patients with Weight Loss,"	
	Int J. Biochem Cell Biol 37(10):2196-	206 (2005) Abstract.		
EXAMINER:		DATE CONSIDERED:		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next communication to applicant.
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the

PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

Form PTO-1449			Attorney's Docket No.	Application Serial No.			
			39780-2830 P1C15	10/006,116			
INFORMATION DISCLOSURE STATEMENT			Applicant(s)				
				n P. BAKER, et al.			
			Filing Date:	Group Art Unit:			
(ι	ise sev	eral sheets if necessary)	December 6, 2001	1636			
		(	OTHER DOCUMENTS				
			hor, title, date, pertinent pages, etc				
	<b>57</b> .	Kogo, H., et al., "Cell Type-Specific Od Distinct mRNAs," J Biol Chem 279(2		-1beta in the Lung caused by Expression of			
	58.	Kommoss, F., et al., "Oncogene and 0 155:19-24 (1992) Abstract.	Growth Factor Expression in Ovaria	an Cancer," Acta Obstet Gynecol Scand Suppl			
				ncer: Quantitative Analysis of mRNA for			
·	59.	Subtypes 1-5 and Correlation with Reg 92(2):175-86 (2005) Abstract.	ceptor Protein Expression and Tur	nor Pathology," <i>Breast Cancer Res. Treat.</i> -			
	60.	Kuo, C.C., et al., "A Transcriptomic ar Leukemia Cells," <i>Proteomics</i> - <u>5(4)</u> :89		of CpG-ODN on Human THP-1 Monocytic			
	61.		ion and Age-dependent Changes o	f the regulatory Subunits of cAMP-dependent			
· ·				on in Colorectal Cancer by RT-PCR and			
	62.			Pathol 198(2):198-206 (2002) Abstract.			
				Protein (MRP) mRNA and Protein in Normal			
	63.		aemopoietic Cells," <i>Br J, Haematol.</i> - <u>94(1)</u> :23-33 (1996) Abstract.				
	64.	Lemstrom, K.B., et al., "Vascular Endothelial Growth Factor Enhances Cardiac Allograft Arteriosclerosis," Circulation - 105(21):2524-30 (2002) Abstract.					
	CE		s of Arachidonic Acid-Sensitive Ta	ndem-Pore Domain Potassium Channels in Rat			
	65.	<b>Experimental Acute Cerebral Ischemia</b>					
	66.	Li, Y., et al., "Retinal Preconditioning 44(3):1299-304 (2003) Abstract.	and the Induction of Heat-Shock P	rotein 27," Invest Ophthalmol Vis Sci			
	67.	Lindberg, P., et al., "Increasing Expression of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor Type 2 in Dog Gingival Tissues with Progressive Inflammation," Arch Oral Biol 46(1):23-31 (2001) Abstract.					
				Reverse Transcription Polymerase Chain			
	68.	Reaction Analyses," <u>15(9)</u> :979-87 (200					
	69.		Overexpressed in Pancreatic Can	cer and in Dysplastic Lesions in Chronic			
				oked Hormone-Receptor Complex in HEK 293			
:	70.	Cells," J Mol Endocrinol 32(1):247-5		mod from the recoptor of inprox in fight 200			
	71.		s and Estrogen Receptor Gene Ex	pression Pattern in the Rat Uterine Epithelium			
	70			bunit of the NMDA Receptor are Differentially			
	72.	Distributed in Human and Rat Forebra					
	73.	Mezzano, S.A., et al., "Overexpression Membranous Nephropathy," Kiney Int	n of Chemokines, Fibrogenic Cytok				
	74.		upling Protein Expression and Intr	amyocytic Triglyceride Depletion in Formerly			
		Miralles, C.P., et al., "Differential Expr		as of the Gamma 2 Subunit of the			
	75.	GABAA/benzodiazepine Receptors," I					
	76			enger Ribonucleic Acid are Present in the			
	76.	Bovine Cervix and Can Regulate Cerv	ical Prostanoid Synthesis," <i>Biol Re</i>	eprod 61(3):776-84 (1999) Abstract.			
	77.	Monaghan, P., et al., "The Alpha(v)bet	beta6 Integrin Receptor for Foot-and-Mouth Disease Virus is Expressed				
	11.	Constitutively on the Epithelial Cells	s Targeted in Cattle," <i>J Gen Virol.</i> - <u>86(Pt 10)</u> :2769-80 (2005) Abstract.				
EXAMINER:			DATE CONSIDERED				

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next communication to applicant.
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted

PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2244524 v1

	Form PTO-1449	Attorney's Docket No.	Application Serial No.				
		39780-2830 P1C15	10/006,116				
INFORMATION DISCLOSURE STATEMENT		Applicant(s)					
		Kevin P. BAKER, et al.					
		Filing Date:	Group Art Unit:				
(use sev	eral sheets if necessary)	December 6, 2001	1636				
	(	OTHER DOCUMENTS					
		hor, title, date, pertinent pages, etc.)					
78.	Montuori, N., et al., "Urokinase-Mediat Small Cell Lung Carcinoma," <i>Int J Car</i>	ed Posttranscriptional Regualtion of Urokina acer - 105(3):353-60 (2003) Abstract.	ase-Receptor Expression in Non				
79.		al Growth Factor Expression Correlates with ioblastomas," <i>Int J Cancer</i> - <u>106(6)</u> :848-55 (2					
80.	Nie, Y., et al., "DNA Hypermethylation	is a Mechanism for Loss of Expression of thas," Carcinogenesis - 22(10):1615-23 (2001)	ne HLA Class I Genes in Human				
81.		mmunohistochemical Analysis of HER2/neu					
82.		ression of Heat Shock Protein 70 in Well He	aling and Chronic Human Wound				
83.		dy of Gene Copy Numbers, Transcripts, and onal Cell Carcincomas," <i>Mol Cell Proteomics</i>					
84.		dy of Gene Copy Numbers, Transcripts, and onal Cell Carcinomas," <i>Molecular &amp; Cellular</i>					
85.	Pachmann, K., et al., "Expression of bcr-abl mRNA in Individual Chronic Myelogenous Leukaemia Cells as determined by in Situ Amplification," Br J. Haematol - 112(3):749-59 (2001) Abstract.						
86.		Pairon, J.C., et al., "Cell Localization and Regulation of Expression of Cytochrome P450 1A1 and 2B1 in Rat Lung after Induction with 3-Methylcholanthrene Using mRNA Hybridization and Immunohistochemistry," Am J Respir Cell Mol					
87.	Papotti, M., et al., "Correlative Immunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis of Somatostatin Receptor Type 2 in Neuroendocrine Tumors of the Lung," <i>Diagn Mol Pathol.</i> - 9(1):47-57 (2000) Abstract.						
88.	Papotti, M., et al., "Expression of Som Endocrine Tumors. A correlative Imm Analysis," Virchows Arch 440(5):461	atostatin Receptor Types 1-5 in 81 Cases if ( unohistochemical and Reverse-Transcriptas I-75 (2002) Abstract.	Gastrointestinal and Pancreatic se Polymerase Chain Reaction				
89.	Paredes, J., et al., "P-Cadherin Overex is Associated with CDH3 Promoter Hy	pression is an Indicator of Clinical Outcome pomethylation," <i>Clin Cancer Res.</i> - <u>11(16)</u> :58	69-77 (2005) Abstract.				
90.	Politis, I., et al., "Mammary-Derived Gr Different Physiological States of the G	rowth Inhibitor Protein and Messenger Ribor iland," <i>J Dairy Sci.</i> - <u>75(6)</u> :1423-9 (1992) Abst	nucleic Acid Concentrations in tract.				
91.	Preesman, A.H., et al., "T-Cell Receptor V Beta-family Usage in Primary Cutaneous and Primary Nodal T-cell non-Hodgkin's Lymphomas," J Invest Dermatol 99(5):587-93 (1992) Abstract.						
92.	Pullig, O., et al., "Matrilin-3 in Human Articular Cartilage: Increased Expression in Osteoarthritis," Osteoarthritis Cartilage - 10(4):253-63 (2002) Abstract.						
93.	Rey, C., et al., "Up-regulation of Mitochondrial Peripheral Benzodiazepine Receptor Expression by Tumor Necrosis Factor Alpha in Testicular Leydig Cells. Possible Involvement in Cell Survival," <i>Biochem Pharmacol.</i> - 60(11):1636-46 (2000) Abstract.						
94.	Cervical Cancer," Am J. Clin Pathol						
95.	Tissues: An Immunochemical Approa	ribution of Laminin Alpha1 and Alpha2 Chai ch," <i>Exp Cell Res.</i> - <u>275(2)</u> :189-99 (2002) Abs	tract.				
96.	Sedelies, K.A., et al., "Discordant Reg   Biol Chem <u>279(25)</u> :26581-7 (2004) Al	ulation of Granzyme H and Granzyme B Explostract.	ression in Human Lymphocytes," J				

EXAMINER:	DATE CONSIDERED:					
	DATE CONCIDENCES.					
•						
EXAMINER: Initial if citation considered, whether or not the citation conf	orms with MPEP 609. Draw a line through the citation if not in					
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						
comormance and not considered. Include a copy of this form with next of	communication to applicant.					

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2244524 v1

	erial No.				
39780-2830 P1C15 10/006,116					
INFORMATION DISCLOSURE STATEMENT Applicant(s)					
Kevin P. BAKER, et al.					
Filing Date: Group Art Unit					
(use several sheets if necessary) December 6, 2001 1636					
OTHER DOCUMENTS					
(including author, title, date, pertinent pages, etc.)					
97. Shen, Y., et al., "BCL2 Protein Expression Parallels its mRNA level in normal and Maligent B Cells	," Blood -				
104(9):2936-9 (2004) Abstract.					
Shinohara, Y., et al., "Quantitative Determinations of the Steady Transcript Levels of Hexokinase I					
98. Glucose Transporter Isoforms in Normal Rat Tissues and the Malignant Tumor Cell Line AH130," I	Biochim Biophys Acta				
- 1368(1):129-36 (1998) Abstract.					
Silvers, A.L., et al., "UVA Irradiation-Induced Activation of Activator Protein-1 is Correlated with In					
99. AP-1 Family Memebers in the Human Keratinocyte Cell Line HaCat," <i>Photochem Photbiol.</i> - 75(3):	302-10 (2002)				
Abstract.	O - Waster				
100. Song, L., et al., "Rat Kidney Glutamyl Aminopeptidase (aminopeptidase A): Molecular Identity and	Cellular				
Localization," Am J. Physiol 267(4 Pt 2):F546-57 (1994) Abstract.	OL.				
101. Spaziani, E.P., et al., "Tumor Necrosis Factor-Alpha Upregulates the Prostaglandin E2 EP1 Recept Cyclooxgenase-2 Isoform in Cultured Amnion WISH Cells," <i>J Interferon Cytokine Res.</i> - 18(12):103					
Spika, I., et al., "Transcriptional Activity of Potent Glucocorticoids: Relevance of Glucocorticord R					
102. Drug Metabolites," <i>Skin Pharmacol Appl Skin Physiol.</i> - 16(3):143-50 (2003) Abstract.	receptor isoforms and				
Splinter D.L. et al. "Specific Inhibition of AOD1 Water Channels in Isolated Bet Introhenatio Bile I	Duct Unite by Small				
	Splinter, P.L., et al., "Specific Inhibition of AQP1 Water Channels in Isolated Rat Intrahepatic Bile Duct Units by Small Interfering RNAs," J Biol Chem - 278(8):6268-74 (2003) Abstract.				
Steams M.E. et al. "Type IV Collagenase (M/r) 72 000) Expression in Human Proctate: Pening an	d Malianant Ticque "				
104.   Cancer Res <u>53(4)</u> :878-83 (1993) Abstract.	u manghant 1155ue,				
Stein P. et al. "The Decomposated Detruger III: Impact of Bladder Outlet Obstruction on Serson	plasmic Endonlasmic				
105. Reticulum Protein and Gene Expression," <i>J Urol.</i> - 164(3Pt 2):1026-30 (2000) Abstract.	oldonno Endopidonno				
Strickland Let al. "TNE-Alpha and II - 8 are Unregulated in the Enidermic of Normal Human Skin.	after UVB Exposure:				
106.   Correlation with Nuetrophil Accumulation and E-Selectin Expression," <i>J Invest Dermatol.</i> - 108(5):					
107. Strutz, F., et al., "Basic Fibroblast Growth Factor Expression is Increased in Human Renal Fibroge					
Mediate Acutocrine Fibroblast Proliferation," <i>Kidney Int.</i> - <u>57(4)</u> :1521-38 (2000) Abstract.					
	Takahashi, K., et al., "Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-Positive Monocytes in				
Mice, " J Biol. Chem <u>278(47)</u> :46654-60 (2003) Abstract.	-				
109. Takimoto, Y., et al., "Augmented Expression of Neuronal Nitric Oxide Synthase in the Atria Parasy	mpthetically				
Decreases Heart Rate During Acute Myocardial Infarction in Rats," <i>Circulation</i> - 105(4):490-6 (2002)					
110. Telek, G., et al., "Differential Upregulation of Cellular Adhesion Molecules at the Sites of Oxidative	Stress in				
Experimental Acute Paricreatitis, J Surg Res 90[1]:50-07 (2001) Abstract.					
111. Timchenko, L., et al., "Myotonic Dystrophy: An Unstable CTG Repeat in a Protein Kinase Gene," S	Semin Cell Biol				
<u>6(1)</u> :13-9 (1995) Abstract.					
112. Torronen, R., et al., "Induction of Class 3 Aldehyde Dehydrogenase in the Mouse Hepatoma Cell L	ine Hepa-1 by Various				
Chemicals," <i>Chem Biol. Interact.</i> - <u>83(2)</u> :107-19 (1992) Abstract.	£11				
Ullmannova, V., et al., "Relationship Between Cyclin D1 and p21 (Waf1/Cip1) During Differentiation	n of Human Wyeloid				
Leukemia Cell Lines," Leuk Res 27(12):1115-23 (2003) Abstract.	duda Danilana A				
Van Beers, E.H., et al., "Intestinal Carbamoyl Phosphate Synthase I in Human and Rat. Expression 114. Shows Species Differences and Mosaic Expression in Duodenum of Both Species." J Histochem (					
<ul> <li>114. Shows Species Differences and Mosaic Expression in Duodenum of Both Species," J Histochem 6</li> <li>40 (1998) Abstract.</li> </ul>	Суюспет <u>46(Z)</u> :231-				
Van Der Wilt C.L. et al. "Expression of Deavyortiding Kingso in Leuksomic Colls Compared with	Solid Tumour Call				
Lines, Liver Metastases and Normal Liver," <i>Eur J Cancer</i> - 39(5):691-7 (2003) Abstract.	Sona Fundar Cen				
Waldherr R at al "Expression of Cytokines and Grouth Eagters in Human Glomerylananhvitidas					
116. 7(4):471-8 (1993) Abstract.	s, . auidu 148411101. •				
EXAMINER: DATE CONSIDERED:					

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2244524 v1

	Form PTO-1449	Attorney's Docket No.	Application Serial No.		
INFORMATION DISCLOSURE STATEMENT		39780-2830 P1C15	10/006,116		
		Applicant(s)  Kevin P. BAKER, et al.			
		Filing Date:	Group Art Unit:		
(use sev	eral sheets if necessary)	December 6, 2001	1636		
OTHER DOCUMENTS					
(including author, title, date, pertinent pages, etc.)					
117.	Walmer, D.K., et al., "Malignant Transformation of the Human Endometrium is associated with Overexpression of Lactoferrin Messenger RNA and Protein," <i>Cancer Res.</i> - <u>55(5)</u> :1168-75 (1995) Abstract.				
118.	Wang, J., et al., "Cell Proliferation in Human Soft Tissue Tumors Correlates with Platelet-derived Growth Factor B Chain Expression: An Immunohistochemical and in Situ Hybridization Study," Cancer Res 54(2):560-4 (1994) Abstract.				
119.	Wang, J., et al., "Expression of Cadherins and Catenins in Paired Tumor and Non-neoplastic Primary Prostate Cultures and Corresponding Prostatectomy Specimens," <i>Urol Res.</i> - 28(5):308-15 (2000) Abstract.				
	Wang, L.G., et al., "Down-Regulation of	of Prostate-Specific Antigen Expression by F	inasteride through Inhibition of		
120.	Complex Formation Between Androgen Receptor and Steroid Receptor-binding Consensus in the Promoter of the PSA				
	Gene in LNCaP Cells," Cancer Res <u>57(4)</u> :714-9 (1997) Abstract.  Weterman, M.A., et al., "Expression of Calcyclin in Human Melanocytic Lesions," Cancer Res <u>53(24)</u> :6061-6 (1993)				
121.	Abstract.	Abstract.			
122.	Williams, E.T., et al., "Estrogen Regulation of the Cytochrome P450 3A Subfamily in Humans," J Pharmacol Exp Ther. 311(2):728-35 (2004) Abstract.				
123.	Wojtaszek, P.A., et al., "Severely Decreased MARCKS Expression Correlates with Ras Reversion but not with Mitogenic Responsiveness" Oncogene - 8(3):755-60 (1993) Abstract.				
124.	Zhong, W., et al., "Expression of Superoxide Dismutases, Catalase, and Glutathione Peroxidase in Glioma Cells," Free Radic Biol Med 27(11-12):1334-45 (1999) Abstract.				
125.	Xi, L., et al., "Expression of Human Telomerase Reverse Transcriptase in Cervix Cancer and its Significance," Zhonghua Fu Chan Ke Za Zhi - 40(6):407-10 (2005) Abstract.				
	2 Enongrida i d Orian Ne Za Zin - 40(0).4	07-10 (2003) Abstract.			
126.	Alberts, B., et al., Molecular Biology of	f the Cell (3rd ed. 1994) Cell 3rd at 453 Figure	9-2 of Cell 3rd Cell 3rd at 403		
127.	Alberts, B., et al., Molecular Biology of the Cell (4 <sup>rd</sup> ed.) In Cell 4 <sup>th</sup> , Figure 6-3 on page 302 Figure 6-90 on page 364 of Cell 4 <sup>th</sup> at 364 Cell 4 <sup>th</sup> at 379				
	Aust, G., et al., "Human Throid Carcing	Aust, G., et al., "Human Throid Carcinoma Cell Lines and Normal Thyrocytes: Expression and Regulation of Matrix			
128.	Metalloproteinase-1 and Tissue Matrix Metalloproteinase Inhibitor-` Messenger-RNA and Protein," <i>Thyroid -7(5)</i> :713-724 (1997)				
129.	Beà, S., et al., "BMI-1 Gene Amplification and Overexpression in Hematological Malignancies Occur Mainly in Mantle Cell Lymphomas," Cancer Research - 61:2409-2412 (2001)				
130.	Beer, et al, "Gene-expression profiles predict survival of patients with lung adenocarcinoma," Nature Biomedicine - 98(6):816-824 (2002)				
131.	Frohnert, B.I. et al., "Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene," J. Biol. Chem. 274:3970-3977 (1999).				
132.	Futcher, B., et al., "A Sampling of the Yeast Proteome," Molecular and Cellular Biology - 19(11):7357-7368 (1999)				
133.	Giovanni, P. N., et al., "Molecular and Immunohistochemical Analysis of HER2/neu Oncogene in Synovial Sarcoma,"  Human Pathology - 34(7):639-645 (2003)				
134.	Gnatenko, D.V., et al., "Transcript Profiling of Human Platelets Using Microarray and Serial Analysis of Gene Expression," <i>Blood</i> - 101(6):2285-2293 (2003)				
		NA Expression and Protein Abundance Data	a: An Approach for the Comparison		
135.		ellular Population of Proteins and Transcrip			
136.	Gromova, I., et al., "Protein Abundancy	y and mRNA Levels of the Adipocyte-Type F	atty Acid Binding Protein Correlate in		
130.	Non-Invasive and Invasive Bladder Tra	ansitional Cell Carcinomas," International Jo	urnal of Oncology - <u>13(2)</u> 6 pages		

EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				
conformance and not considered. Include a copy of this form with next communication to applicant.				
*If an asterisk is placed beside the reference number, a copy is not provide	ded because the reference was previously cited by or submitted to the			

PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2244524 v1

Form PTO-1449		Attorney's Docket No. 39780-2830 P1C15	Application Serial No. 10/006,116		
INFORMATIO	N DISCLOSURE STATEMENT	Applicant(s)	10.000,110		
III GI(III) (1161) 5165 266 11 677 (1211)		Kevin P. BAKER, et al.			
		Filing Date:	Group Art Unit:		
(use sev	eral sheets if necessary)	December 6, 2001	1636		
	(1998)				
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)					
137.	Hähnel, E., et al., "Expression of the pS2 Gene in Breast Tissues Assessed by pS2-mRNA Analysis and pS2-Protein Radioimmunoassay," Breast Cancer Research and Treatment - 24:71-74 (1992)				
138.	Hirsch, F.R., et al., "Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology," Clinical Cancer Research - 7:5-22 (2001)				
139.	Holten-Andersen, M.D., et al., "Localization of Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) in Human Colorectal Adenoma and Adenocarcinoma," Int. J. Cancerl - 113:198-206 (2005)				
140.	Janssens, N., et al., "Alteration of Friz	Janssens, N., et al., "Alteration of Frizzled Expression in Renal Cell Carcinoma," Tumor Biology - 25:161-171 (2004)			
141.	Kammori, M., et al., "Expression of Human Telomerase Reverse Transcriptase Gene and Protein, and of Estrogen and Progesterone Receptors, in Breast Tumors: Preliminary Data from Neo-Adjuvant Chemotherapy", International Journal of Oncology - 27(5) (2005)				
. 142.	Kuo, C.C., et al., "A Transcriptomic and Proteomic Analysis of the Effect of CpG-ODN on Human THP-1 Monocytic Leukemia Cells," Proteomics - 5:894-906 (2005)				
143.	Lewin, B., Genes VI (1997 Genes VI at 847-848				
1,44.	Martin, G. et al., "Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA syntetase genes by PPAR® and PPAR® activators," J. Biol. Chem. 272:28210-28217 (1997).				
145.	Meric, F., et al., "Translation Initiation in Cancer: A Novel Target for Therapy," Molecular Cancer Therapeutics - 1:971-979 (2002)				
146.	Munaut, C., et al., "Vascular Endothelial Growth Factor Expression Correlates With Matrix Metalloproteinases MT1-NMP, MNP-2 and NMP-9 in Human Glioblastomas," Int. J. Cancer - 106:848-855 (2003)				
147.	Maruyama, H., et al., "Id-1 and Id-2 are Overexpressed in Pancreatic Cancer and in Dysplastic Lesions in Chronic Pancreatitis," American Journal of Pathology - 155(3):815-822 (1999)				
148.	Papotti, M., et al., "Correlative Immunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis of Somatostatin Receptor Type 2 in Neuroendocrine Tumors of the Lung," <i>Diagnostic Molecular Pathology</i> - 9(1):47-57 (2000)				
149.	Walmer, D. K., et al., "Malignant Transformation of the Human Endometrium is Associated with Overexpression of Lactoferrin Messenger RNA and Protein," Cancer Research - 55(5):1168-1174 (1995)				
150.	Wang, J., et al., "Expression of Cadherins and Catenins in Paired Tumor and non-Neoplastic Primary Prostate Cultures and Corresponding Prostatectomy Specimens," <i>Urol Resl</i> - 28:308-315 (2000)				
151.	Zhigang, Z., et al., "Prostate Stem Cell Antigen (PSCA) Express in Human Prostate Cancer Tissues and its Potential Role in Prostate Carinogenesis and Progession of Prostate Cancer," World Journal of Surgical Oncology - 2-13 (2004)				
·					

EXAMINER:	•	DATE CONSIDERED:
	•	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35.U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2244524 v1